CEFTAZIDIME

Ceftazidime Adverse Events Reported to the FDA Over Time

How are Ceftazidime adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Ceftazidime, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Ceftazidime is flagged as the suspect drug causing the adverse event.

Most Common Ceftazidime Adverse Events Reported to the FDA

What are the most common Ceftazidime adverse events reported to the FDA?

Renal Failure Acute	85 (2.56%)
Pyrexia	55 (1.66%)
Toxic Epidermal Necrolysis	39 (1.18%)
Dyspnoea	35 (1.06%)
Diarrhoea	34 (1.03%)
Blood Creatinine Increased	29 (.87%)
Renal Tubular Necrosis	29 (.87%)
Renal Failure	28 (.84%)
Multi-organ Failure	27 (.81%)
Thrombocytopenia	27 (.81%)
Hypersensitivity	25 (.75%)
	Show More
Stevens-johnson Syndrome	25 (.75%)
Confusional State	24 (.72%)
Pleural Effusion	24 (.72%)
Death	23 (.69%)
Respiratory Failure	23 (.69%)
Anaemia	22 (.66%)
Urticaria	22 (.66%)
Drug Interaction	21 (.63%)
Renal Impairment	21 (.63%)
Sepsis	21 (.63%)
Convulsion	20 (.6%)
Disseminated Intravascular Coagulat...	20 (.6%)
Rash	20 (.6%)
Anaphylactic Reaction	19 (.57%)
Condition Aggravated	19 (.57%)
Pruritus	19 (.57%)
Hepatic Function Abnormal	18 (.54%)
Tachycardia	18 (.54%)
Aspartate Aminotransferase Increase...	17 (.51%)
Interstitial Lung Disease	17 (.51%)
Rash Maculo-papular	17 (.51%)
Septic Shock	17 (.51%)
Alanine Aminotransferase Increased	16 (.48%)
Hyponatraemia	16 (.48%)
Hypotension	16 (.48%)
Liver Disorder	16 (.48%)
Neutropenia	16 (.48%)
Tremor	16 (.48%)
Vomiting	16 (.48%)
Clostridium Difficile Colitis	15 (.45%)
Nausea	15 (.45%)
Rash Pruritic	15 (.45%)
Clostridium Colitis	14 (.42%)
Drug Hypersensitivity	14 (.42%)
Haemodialysis	14 (.42%)
Headache	14 (.42%)
Hypokalaemia	14 (.42%)
Cardio-respiratory Arrest	13 (.39%)
Chills	13 (.39%)
Malaise	13 (.39%)
Rash Erythematous	13 (.39%)
Status Epilepticus	13 (.39%)
Tachypnoea	13 (.39%)
Coma	12 (.36%)
Dehydration	12 (.36%)
Dizziness	12 (.36%)
Erythema	12 (.36%)
Haemolytic Anaemia	12 (.36%)
Hepatic Failure	12 (.36%)
Pseudomonas Infection	12 (.36%)
Arthralgia	11 (.33%)
Cholestasis	11 (.33%)
Cyanosis	11 (.33%)
Depression	11 (.33%)
Electrocardiogram Qt Prolonged	11 (.33%)
Encephalopathy	11 (.33%)
Eosinophilia	11 (.33%)
Face Oedema	11 (.33%)
Infection	11 (.33%)
Leukopenia	11 (.33%)
Metabolic Acidosis	11 (.33%)
Pancytopenia	11 (.33%)
Pneumonia	11 (.33%)
Purpura	11 (.33%)
Staphylococcal Infection	11 (.33%)
Syncope	11 (.33%)
Anaphylactic Shock	10 (.3%)
Cytolytic Hepatitis	10 (.3%)
Drug Ineffective	10 (.3%)
Drug Level Increased	10 (.3%)
Myoclonus	10 (.3%)
Nystagmus	10 (.3%)
Oedema Peripheral	10 (.3%)
Shock	10 (.3%)
Ascites	9 (.27%)
Asthenia	9 (.27%)
Candidiasis	9 (.27%)
Haemolytic Uraemic Syndrome	9 (.27%)
Herpes Zoster	9 (.27%)
Hyperhidrosis	9 (.27%)
Large Intestine Perforation	9 (.27%)
Megacolon	9 (.27%)
Myocardial Ischaemia	9 (.27%)
Oedema	9 (.27%)
Platelet Count Decreased	9 (.27%)
Pneumonia Aspiration	9 (.27%)
Pseudomembranous Colitis	9 (.27%)
Toxic Skin Eruption	9 (.27%)
Wheezing	9 (.27%)
Cardiac Arrest	8 (.24%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Ceftazidime, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Ceftazidime is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Ceftazidime

What are the most common Ceftazidime adverse events reported to the FDA?

Epidermal And Dermal Conditions	252 (7.6%)
Renal Disorders	193 (5.82%)
Infections - Pathogen Unspecified	171 (5.16%)
Neurological	128 (3.86%)
Respiratory	127 (3.83%)
Hepatic And Hepatobiliary	122 (3.68%)
Bacterial Infectious	104 (3.14%)
Allergic Conditions	73 (2.2%)
Cardiac Arrhythmias	70 (2.11%)
Electrolyte And Fluid Balance Condi...	60 (1.81%)
Body Temperature Conditions	59 (1.78%)
	Show More
White Blood Cell	59 (1.78%)
Gastrointestinal Motility And Defec...	48 (1.45%)
Lower Respiratory Tract Disorders	48 (1.45%)
Gastrointestinal Signs	47 (1.42%)
Hepatobiliary	47 (1.42%)
Renal And Urinary Tract Investigati...	45 (1.36%)
Hematology Investigations	43 (1.3%)
Seizures	43 (1.3%)
Therapeutic And Nontherapeutic Effe...	42 (1.27%)
Anemias Nonhemolytic And Marrow Dep...	41 (1.24%)
Fungal Infectious	40 (1.21%)
Cardiac And Vascular Investigations	36 (1.09%)
Viral Infectious	36 (1.09%)
Coagulopathies And Bleeding Diathes...	34 (1.03%)
Deliria	32 (.96%)
Platelet	32 (.96%)
Pleural	29 (.87%)
Decreased And Nonspecific Blood Pre...	28 (.84%)
Gastrointestinal Hemorrhages	28 (.84%)
Movement Disorders	27 (.81%)
Angiedema And Urticaria	26 (.78%)
Urinary Tract Signs	26 (.78%)
Hemolyses And Related Conditions	24 (.72%)
Fatal Outcomes	23 (.69%)
Hematological And Lymphoid Tissue T...	21 (.63%)
Administration Site Reactions	19 (.57%)
Ocular Infections, Irritations And ...	19 (.57%)
Cardiac Disorder Signs	18 (.54%)
Medication Errors	18 (.54%)
Skin Appendage Conditions	18 (.54%)
Bronchial Disorders	17 (.51%)
Encephalopathies	17 (.51%)
Musculoskeletal And Connective Tiss...	17 (.51%)
Water, Electrolyte And Mineral	17 (.51%)
Central Nervous System Vascular	16 (.48%)
Headaches	16 (.48%)
Joint	16 (.48%)
Skin Vascular Abnormalities	16 (.48%)
Coronary Artery	15 (.45%)
Hearing	15 (.45%)
Vascular Hemorrhagic	15 (.45%)
Toxicology And Therapeutic Drug Mon...	14 (.42%)
Glucose Metabolism Disorders	13 (.39%)
Protein And Chemistry Analyses	13 (.39%)
Depressed Mood Disorders	12 (.36%)
Microbiology And Serology	12 (.36%)
Oral Soft Tissue Conditions	12 (.36%)
Peritoneal And Retroperitoneal Cond...	12 (.36%)
Suicidal And Self-injurious Behavio...	12 (.36%)
Acid-base	11 (.33%)
Disturbances In Thinking	11 (.33%)
Gastrointestinal Ulceration And Per...	11 (.33%)
Metastases	11 (.33%)
Spleen, Lymphatic And Reticulendoth...	11 (.33%)
Enzyme	10 (.3%)
Exocrine Pancreas Conditions	10 (.3%)
Eye	10 (.3%)
Maternal Complications Of Labour An...	10 (.3%)
Muscle	10 (.3%)
Protein And Amino Acid Metabolism	10 (.3%)
Vascular	10 (.3%)
Chemical Injury And Poisoning	9 (.27%)
Gastrointestinal Inflammatory Condi...	9 (.27%)
Gastrointestinal Stenosis And Obstr...	9 (.27%)
Immune	9 (.27%)
Increased Intracranial Pressure And...	9 (.27%)
Metabolic, Nutritional And Blood Ga...	9 (.27%)
Neonatal And Perinatal Conditions	9 (.27%)
Ocular Neuromuscular	9 (.27%)
Anxiety Disorders	8 (.24%)
Bile Duct	8 (.24%)
Diabetic Complications	8 (.24%)
Lifestyle Issues	8 (.24%)
Personality Disorders	8 (.24%)
Psychiatric	8 (.24%)
Heart Failures	7 (.21%)
Vascular Hypertensive	7 (.21%)
Anterior Eye Structural Change, Dep...	6 (.18%)
Appetite And General Nutritional	6 (.18%)
Gastrointestinal Vascular Condition...	6 (.18%)
Hematopoietic Neoplasms	6 (.18%)
Immunology And Allergy	6 (.18%)
Injuries	6 (.18%)
Leukemias	6 (.18%)
Mental Impairment	6 (.18%)
Nephropathies	6 (.18%)
Physical Examination Topics	6 (.18%)
Respiratory Tract Therapeutic Proce...	6 (.18%)
Thoracic Disorders	6 (.18%)
Vitamin Related	6 (.18%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Ceftazidime, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Ceftazidime is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.